Review

Diffuse Alveolar Hemorrhage

Authors: Brandi R. Newsome, MD, Juan E. Morales, MD

Abstract

Diffuse alveolar hemorrhage (DAH) is a life-threatening disorder characterized clinically by the presence of hemoptysis, falling hematocrit, diffuse pulmonary infiltrates and hypoxemic respiratory failure. It refers to bleeding that originates in the pulmonary microvasculature instead of the parenchyma or bronchial circulation. DAH should be considered a medical emergency due to the morbidity and mortality associated with failure to treat the disorder promptly. Pulmonary renal syndromes, connective tissue disorders and drugs make up the majority of the cases of DAH. The treatment of DAH ranges from supportive care and withdrawal of offending drugs to high-dose steroids, immunosuppresents and plasmapharesis. The following review will discuss the clinical, radiographic and pathologic findings in a variety of disorders that cause DAH. Standard treatment options, as well as new treatment options will also be discussed.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Collard HR, Schwarz MI. Diffuse alveolar hemorrhage. Clin Chest Med 2004;25:583-592, vii.
 
2. Travis WD, Colby TV, Lombard C, et al. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 1990;14:1112-1125.
 
3. Zamora MR, Warner ML, Tuder R, et al. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore)1997;76:192-202.
 
4. Greening AP, Hughes JM. Serial estimations of carbon monoxide diffusing capacity in intrapulmonary haemorrhage. Clin Sci (Lond) 1981;60:507-512.
 
5. Mark EJ, Ramirez JF. Pulmonary capillaritis and hemorrhage in patients with systemic vasculitis. Arch Pathol Lab Med 1985;109:413-418.
 
6. Fontenot AP, Schwarz A, Marvin I. Diffuse alveolar hemorrhage. In: Schwarz MI, Talmadge E, eds. Interstitial Lung Disease. Hamilton, ON, Canada: BC Decker; 2003:632-656.
 
7. Hasleton PS. Adult respiratory distress syndrome. In: Hasleton PS, ed. Spencer's Pathology of the Lung. New York: McGraw-Hill; 1996:375-400.
 
8. Heslet L, Nielsen JD, Levi M, et al. Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. Crit Care 2006;10:R177.
 
9. Estella A, Jareno A, Perez-Bello Fontaina L. Intrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories. Cases J 2008;1:150.
 
10. Sindet-Pedersen S, Ramstrom G, Bernvil S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med 1989;320:840-843.
 
11. Taghaddomi RJ, Mirzaee A, Attar AS, et al. Tranexamic acid reduces blood loss in off-pump coronary artery bypass surgery. J Cardiothorac Vasc Anesth 2009;23:312-315.
 
12. Solomonov A, Fruchter O, Zuckerman T, et al. Pulmonary hemorrhage: a novel mode of therapy. Respir Med 2009;103:1196-1200.
 
13. Sanders M, Spies CD, Martiny V, et al. Mortality associated with administration of highdose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care2010;14:R148.
 
14. Cordier JF, Valeyre D, Guillevin L, et al. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. Chest 1990;97:906-912.
 
15. Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003;42:1149-1153.
 
16. Nguyen T, Martin MK, Indrikovs AJ. Plasmapheresis for diffuse alveolar hemorrhage in a patient with Wegener's granulomatosis: case report and review of the literature. J Clin Apher 2005;20:230-234.
 
17. Matthay RA, Schwarz MI, Petty TL, et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975;54:397-409.
 
18. Teague CA, Doak PB, Simpson IJ, et al. Goodpasture's syndrome: an analysis of 29 cases. Kidney Int 1978;13:492-504.
 
19. Fouret PJ, Touboul JL, Mayaud CM, et al. Pulmonary Kaposi's sarcoma in patients with acquired immune deficiency syndrome: a clinicopathological study. Thorax 1987;42:262-268.
 
20. Vincent B, Flahault A, Antoine M, et al. AIDS-related alveolar hemorrhage: a prospective study of 273 BAL procedures. Chest 2001;120:1078-1084.
 
21. Afessa B, Tefferi A, Litzow MR, et al. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002;166:1364-1368.
 
22. Majhail NS, Parks K, Defor TE, et al. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes.Biol Blood Marrow Transplant 2006;12:1038-1046.
 
23. Lewis ID, DeFor T, Weisdorf DJ. Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy. Bone Marrow Transplant2000;26:539-543.
 
24. Wanko SO, Broadwater G, Folz RJ, et al. Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid. Biol Blood Marrow Transplant 2006;12:949-953.
 
25. Milman N, Pedersen FM. Idiopathic pulmonary haemosiderosis. Epidemiology, pathogenic aspects and diagnosis. Respir Med 1998;92:902-907.
 
26. Byrd RB, Trunk G. Systemic lupus erythematosus presenting as pulmonary hemosiderosis. Chest 1973;64:128-129.
 
27. Leaker B, Cambridge G, du Bois RM, et al. Idiopathic pulmonary haemosiderosis: a form of microscopic polyarteritis? Thorax 1992;47:988-990.
 
28. Kuhn C. Systemic lupus erythematosus in a patient with ultrastructural lesions of the pulmonary capillaries previously reported in the review as due to idiopathic pulmonary hemosiderosis. Am Rev Respir Dis 1972;106:931-932.
 
29. Chryssanthopoulos C, Cassimos C, Panagiotidou C. Prognostic criteria in idiopathic pulmonary hemosiderosis in children. Eur J Pediatr 1983;140:123-125.
 
30. Saeed MM, Woo MS, MacLaughlin EF, et al. Prognosis in pediatric idiopathic pulmonary hemosiderosis. Chest 1999;116:721-725.
 
31. Ioachimescu OC, Sieber S, Kotch A. Idiopathic pulmonary haemosiderosis revisited. Eur Respir J 2004;24:162-170.
 
32. Wroblewski BM, Stefanovic CR, McDonough VM, et al. The challenges of idiopathic pulmonary hemosiderosis and lung transplantation. Crit Care Nurse 1997;17:39-44.
 
33. Calabrese F, Giacometti C, Rea F, et al. Recurrence of idiopathic pulmonary hemosiderosis in a young adult patient after bilateral single-lung transplantation. Transplantation 2002;74:1643-1645.
 
34. Louie S, Gamble CN, Cross CE. Penicillamine associated pulmonary hemorrhage. J Rheumatol 1986;13:963-966.
 
35. Vizioli LD, Cho S. Amiodarone-associated hemoptysis. Chest 1994;105:305-306.
 
36. Iskander S, Raible DG, Brozena SC, et al. Acute alveolar hemorrhage and orthodeoxia induced by intravenous amiodarone. Catheter Cardiovasc Interv 1999;47:61-63.
 
37. Meyer MM, Meyer RJ. Nitrofurantoin-induced pulmonary hemorrhage in a renal transplant recipient receiving immunosuppressive therapy: case report and review of the literature. J Urol 1994;152:938-940.
 
38. Vincent F, Bensousan TA. Re: nitrofurantoin-induced pulmonary hemorrhage in a renal transplant recipient receiving immunosuppressive therapy: case report and review of the literature. J Urol 1995;154:214.
 
39. Morales JE, Iltchev D, Allen JN, et al. Life-threatening diffuse alveolar hemorrhage related to crack cocaine use: spontaneous resolution without steroids. Chest 2003;124(suppl):243S.
 
40. Bailey ME, Fraire AE, Greenberg SD, et al. Pulmonary histopathology in cocaine abusers. Hum Pathol 1994;25:203-207.
 
41. Baldwin GC, Choi R, Roth MD, et al. Evidence of chronic damage to the pulmonary microcirculation in habitual users of alkaloidal ("crack") cocaine. Chest 2002;121:1231-1238.
 
42. Iskandar SB, Kasasbeh ES, Mechleb BK, et al. Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors. J Interv Cardiol 2006;19:356-363.
 
43. Kalra S, Bell MR, Rihal CS. Alveolar hemorrhage as a complication of treatment with abciximab.Chest 2001;120:126-131.
 
44. Cannageiter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical prosthetic heart valve prostheses. Circulation 1994;89:635-641.
 
45. Ananthasubramaniam K, Beattie JN, Rosman HS, et al. How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? Chest 2001;119:478-484.